Mentioned in ?
References in periodicals archive ?
There are no large outcome studies, but it seems to be most useful in patients with unexplained or premature arteriosclerotic cardiovascular disease in the face of otherwise normal lipids," Dr.
Consider six markers for CV risk assessment
Tokyo, Japan, Oct 28, 2005 - (JCNN) - Daiichi Sankyo announced on October 26 that its subsidiary Sankyo has decided to cease its ongoing clinical studies of pactimibe (CS-505), an investigational drug for the treatment of arteriosclerotic cardiovascular disease (ASCVD).
Sankyo Ceases Clinical Studies of Pactimibe, Investigational Drug for ASCVD
Patients with chronic renal disease have high morbidity and mortality resulting from arteriosclerotic cardiovascular disease (CVD).
Development of a novel enzymatic cycling assay for total homocysteine

Medical browser ?
Full browser ?